BioCryst Pharma (BCRX) Tops Q4 EPS by 1c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.97 +2.36%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $6.34 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
- BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
